Research Analysts Issue Forecasts for RNAC FY2025 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Cartesian Therapeutics in a report released on Monday, March 17th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of ($3.65) per share for the year. Cantor Fitzgerald has a “Hold” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is $4.56 per share.

Several other analysts have also commented on RNAC. Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Cartesian Therapeutics in a research report on Thursday, March 13th. HC Wainwright lowered their price objective on shares of Cartesian Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, March 14th. Finally, BTIG Research started coverage on shares of Cartesian Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $42.00 price objective on the stock. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.14.

Cartesian Therapeutics Stock Performance

Cartesian Therapeutics stock opened at $15.93 on Wednesday. Cartesian Therapeutics has a fifty-two week low of $11.67 and a fifty-two week high of $41.87. The stock has a market cap of $412.70 million, a PE ratio of -0.30 and a beta of 0.71. The firm’s 50-day simple moving average is $18.41 and its 200 day simple moving average is $18.72.

Institutional Trading of Cartesian Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MPM Bioimpact LLC increased its holdings in Cartesian Therapeutics by 14.6% during the 4th quarter. MPM Bioimpact LLC now owns 721,139 shares of the company’s stock worth $12,916,000 after acquiring an additional 91,716 shares during the period. Nuveen Asset Management LLC grew its stake in Cartesian Therapeutics by 197.8% in the 4th quarter. Nuveen Asset Management LLC now owns 72,099 shares of the company’s stock worth $1,291,000 after buying an additional 47,889 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Cartesian Therapeutics by 44.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,786 shares of the company’s stock worth $104,000 after buying an additional 1,789 shares in the last quarter. Bank of America Corp DE grew its stake in Cartesian Therapeutics by 54.4% in the 4th quarter. Bank of America Corp DE now owns 11,690 shares of the company’s stock worth $209,000 after buying an additional 4,120 shares in the last quarter. Finally, 683 Capital Management LLC grew its stake in Cartesian Therapeutics by 65.7% in the 4th quarter. 683 Capital Management LLC now owns 125,000 shares of the company’s stock worth $2,239,000 after buying an additional 49,569 shares in the last quarter. Institutional investors own 86.95% of the company’s stock.

Insider Activity

In related news, CTO Metin Kurtoglu sold 2,458 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $16.83, for a total transaction of $41,368.14. Following the sale, the chief technology officer now owns 62,258 shares of the company’s stock, valued at approximately $1,047,802.14. This represents a 3.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Blaine Davis sold 4,028 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $16.83, for a total transaction of $67,791.24. Following the sale, the chief financial officer now directly owns 94,811 shares in the company, valued at $1,595,669.13. This trade represents a 4.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,744 shares of company stock valued at $247,337 over the last quarter. Company insiders own 57.90% of the company’s stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.